Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
16 Matthias Tschp and his team discovered that dual agonists targeting both GLP-1 and GIP receptors (GIPR) are more effective in treating diabetes than those targeting only GLP-1R
BPC-157, on the other hand, is based on a gastric peptide and is known for its healing properties
There are no known health risks associated with using this injection
Compared to GHK-Cu (340 Da tripeptide), BPC-157 preferentially targets deep tissues and visceral healing, while GHK-Cu focuses on skin and dermal collagen production
Among these illnesses are Alzheimers, multiple sclerosis, Bells palsy, neuropathies, Crohns, even autism
This product is supplied strictly for laboratory research purposes only
US$ 22.04
US$ 26.94
US$ 24.78
US$ 26.59
/product/19/3469114/1.jpg?9363)
US$ 20.82
US$ 21.39
US$ 20.03
US$ 21.09
US$ 23.78
